​

EyePoint Pharmaceuticals Ownership | Who Owns EyePoint Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

EyePoint Pharmaceuticals Ownership Summary

EyePoint Pharmaceuticals is owned by 93.81% institutional investors, 2.90% insiders, and 3.30% retail investors. Cormorant asset management, lp is the largest institutional shareholder, holding 11.91% of EYPT shares. Federated Hermes Kaufmann R is the top mutual fund, with 2.96% of its assets in EyePoint Pharmaceuticals shares.

EYPT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEyePoint Pharmaceuticals93.81%2.90%3.30%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Cormorant asset management, lp8.32M11.91%$118.55M
Suvretta capital management6.19M8.86%$88.18M
Adage capital partners gp5.56M7.95%$79.17M
Blackrock3.76M7.12%$32.75M
Blackrock funding, inc. /de4.96M7.10%$70.69M
Federated hermes4.42M6.32%$62.89M
Franklin resources4.17M5.97%$59.41M
Vanguard group3.79M5.43%$54.03M
Tcg crossover management3.57M5.11%$50.87M
Paradigm biocapital advisors lp2.01M2.87%$28.56M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cormorant asset management, lp8.32M8.18%$118.55M
5am venture management1.05M5.48%$14.95M
Essex woodlands management1.08M5.03%$15.45M
Patient square capital lp1.01M3.85%$14.41M
Rosalind advisors650.00K3.16%$9.26M
Tcg crossover management3.57M2.50%$50.87M
Suvretta capital management6.19M2.26%$88.18M
Blue owl capital lp367.59K1.62%$5.23M
Artia global partners lp628.37K1.42%$8.95M
Myda advisors300.00K0.92%$4.27M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp2.01M0.81%2.01M
Orbimed advisors1.80M0.60%1.80M
Blackrock3.76M0.00%977.52K
Rosalind advisors650.00K3.16%650.00K
Millennium management446.20K0.00%446.20K

Top Sellers

HolderShares% AssetsChange
Ra capital management---3.18M
Perceptive advisors---1.54M
Adage capital partners gp5.56M0.13%-1.24M
Octagon capital advisors lp---1.09M
Finepoint capital lp---1.08M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp2.01M0.81%2.01M$28.56M
Orbimed advisors1.80M0.60%1.80M$25.58M
Rosalind advisors650.00K3.16%650.00K$9.26M
Axa investment managers244.43K0.01%244.43K$3.48M
Silverarc capital management230.84K0.44%230.84K$3.29M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Assetmark-15.00
Continuum advisory-16.00
Coldstream capital management-21.00
Park place capital-23.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251569.86%65,594,5981.78%931.10%767.04%4322.86%
Jun 30, 2025147-5.16%68,901,914-5.62%980.90%71-12.35%38-15.56%
Mar 31, 20251574.67%74,070,140-0.48%1060.57%81-16.49%4691.67%
Dec 31, 20241482.78%74,156,37726.76%1361.18%9541.79%24-52.00%
Sep 30, 2024143-8.92%58,500,9580.17%1070.88%68-26.09%489.09%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Federated Hermes Kaufmann R2.04M2.96%-
Federated Hermes Kaufmann Growth2.04M2.96%-
Vanguard Total Stock Mkt Idx Inv2.03M2.94%-44.95K
Franklin Biotechnology Discv A(acc)USD1.91M2.77%-
Vanguard US Total Market Shares ETF1.56M2.27%-
Federated Hermes Kaufmann Small Cap A1.49M2.16%-125.99K
iShares Russell 2000 ETF1.49M2.16%-
Federated Hermes Kaufmann Small Cap Grow1.49M2.15%-125.99K
Franklin US Small Cap Growth Equity1.27M1.84%97.80K
Franklin Small Cap Growth SMA1.27M1.84%1.27M

Recent Insider Transactions

DateNameRoleActivityValue
Dec 04, 2025Cormorant Asset Management, LP Former 10% OwnerSell$942.24K
Dec 04, 2025Lurker Nancy-Sell$140.48K
Nov 28, 2025Lurker Nancy-Sell$7.47K
Nov 26, 2025Lurker Nancy-Sell$2.99K
Nov 11, 2025Ribeiro Ramiro Chief Medical OfficerSell$31.60K

Insider Transactions Trends

DateBuySell
2025 Q4-4
2025 Q3--
2025 Q24-
2025 Q1--
2024 Q341

EYPT Ownership FAQ

Who Owns EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals shareholders are primarily institutional investors at 93.81%, followed by 2.90% insiders and 3.29% retail investors. The average institutional ownership in EyePoint Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which EyePoint Pharmaceuticals exceeds.

Who owns the most shares of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals’s largest shareholders are Cormorant asset management, lp (8.32M shares, 11.91%), Suvretta capital management (6.19M shares, 8.86%), and Adage capital partners gp (5.56M shares, 7.95%). Together, they hold 28.71% of EyePoint Pharmaceuticals’s total shares outstanding.

Does Blackrock own EyePoint Pharmaceuticals?

Yes, BlackRock owns 7.12% of EyePoint Pharmaceuticals, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.75M$. In the last quarter, BlackRock increased its holdings by 977.52K shares, a 35.07% change.

Who is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Cormorant asset management, lp is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 8.18% of its assets in 8.32M EyePoint Pharmaceuticals shares, valued at 118.55M$.

Who is the top mutual fund holder of EyePoint Pharmaceuticals shares?

Federated Hermes Kaufmann R is the top mutual fund holder of EyePoint Pharmaceuticals shares, with 2.96% of its total shares outstanding invested in 2.04M EyePoint Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools